首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD40L |
| Uniprot No | P29965 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 113-261aa |
| 氨基酸序列 | MQKGDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLT VKRQGLYYIYAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTH SSAKPCGQQSIHLGGVFELQPGASVFVNVTDPSQVSHGTGFTSFGLLKL |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"CD40 Ligand as a Potential Immunomodulatory Agent in Cancer Therapy" - Smith et al.**
摘要：研究探讨了重组CD40L蛋白通过激活抗原呈递细胞增强抗肿瘤免疫反应的作用，并与检查点抑制剂联用显示出协同治疗效果。
2. **"Recombinant CD40L Protein Enhances Vaccine Efficacy in a Murine Model" - Zhang et al.**
摘要：验证了重组CD40L作为疫苗佐剂的功能，通过激活树突状细胞和促进T细胞活化，显著提高疫苗诱导的抗原特异性抗体和细胞免疫应答。
3. **"Structural and Functional Characterization of a Soluble CD40L Mutant for Autoimmune Disease Intervention" - Lee et al.**
摘要：报道了一种工程化可溶性CD40L蛋白，通过阻断CD40-CD40L信号通路抑制自身免疫反应，在类风湿性关节炎模型中减轻炎症和组织损伤。
4. **"CD40L Recombinant Protein Modulates B Cell Maturation in Chronic Infection" - Kumar et al.**
摘要：研究揭示重组CD40L通过促进B细胞增殖和抗体类别转换，增强慢性感染模型中的病原体清除能力，为免疫缺陷疾病提供治疗策略。
(注：以上文献为示例，实际引用需核对真实出版物信息。)
CD40 ligand (CD40L), also known as CD154. is a transmembrane protein belonging to the tumor necrosis factor (TNF) superfamily. It plays a pivotal role in regulating adaptive immune responses by binding to its receptor CD40. a member of the TNF receptor family expressed on antigen-presenting cells (APCs), B cells, and endothelial cells. This interaction is essential for T cell-dependent activation of B cells, antibody class switching, germinal center formation, and dendritic cell maturation. Dysregulation of CD40-CD40L signaling has been implicated in autoimmune diseases, chronic inflammation, and cancer.
Recombinant CD40L proteins are engineered versions designed to mimic the natural ligand's functional properties while overcoming limitations of native membrane-bound forms. These proteins are typically produced using mammalian expression systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and trimerization – a structural requirement for receptor activation. Soluble forms often incorporate fusion tags (e.g., Fc regions) to enhance stability and prolong serum half-life. Alternatively, membrane-anchored versions can be expressed on cell surfaces for localized signaling.
In research, recombinant CD40L serves as a critical tool for studying immune cell crosstalk and costimulatory pathways. Therapeutically, it has been explored as an immune adjuvant to boost antitumor responses, particularly in combination with cancer vaccines or checkpoint inhibitors. However, challenges remain in balancing immune activation with potential toxicity, as uncontrolled CD40 signaling may trigger cytokine storms. Recent advances include the development of CD40 agonists with tunable activity and targeted delivery systems to improve specificity. Current clinical trials are evaluating CD40L-based therapies in oncology, vaccine development, and immunodeficiency disorders.
×
